Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 464Lung Neoplasms 147Melanoma 92Squamous Cell Carcinoma of Head and Neck 70Carcinoma, Renal Cell 63Neoplasms 61Colorectal Neoplasms 61Triple Negative Breast Neoplasms 48Neoplasm Metastasis 48Parkinson Disease 4, Autosomal Dominant Lewy Body 44Ovarian Neoplasms 42Stomach Neoplasms 39Small Cell Lung Carcinoma 39Pancreatic Neoplasms 39Carcinoma, Transitional Cell 38Breast Neoplasms 38Head and Neck Neoplasms 34Uterine Cervical Neoplasms 30Endometrial Neoplasms 30Urinary Bladder Neoplasms 26Esophageal Neoplasms 24Carcinoma, Hepatocellular 24Mesothelioma 21Mesothelioma, Malignant 18Kidney Neoplasms 15Prostatic Neoplasms 14Adenocarcinoma of Lung 14Carcinoma 13Colonic Neoplasms 12Cholangiocarcinoma 12

Interventions

zenocutuzumab 1seribantumab 1pembrolizumab 1osimertinib 1enzalutamide 1cemiplimab 1Vascular Endothelial Growth Factor A 1Paroxetine 1Paclitaxel 1Itraconazole 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × pembrolizumab × Thoracic × Clear all
NCT07111520 2026-05-05

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

BioNTech SE

Phase 1/2 Recruiting
420 enrolled
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡